推进 ALS 研究：公私合作加快药物和生物标记物的开发。

IF 14.6 1区医学 Q1 NEUROSCIENCES

Trends in Neurosciences Pub Date : 2024-11-21 DOI:10.1016/j.tins.2024.10.008

Alessio Travaglia, Shubhangi Lal, Sri Ramulu Pullagura

引用次数: 0

摘要

肌萎缩性脊髓侧索硬化症（ALS）的复杂性和分散的研究工作阻碍了开发有效治疗方法的进程。通过促进合作、标准化和包容性，加速药物伙伴关系® (AMP®) ALS 计划旨在为 ALS 生物标志物和治疗方法的未来发现奠定基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advancing ALS research: public-private partnerships to accelerate drug and biomarker development.

Developing effective treatments for amyotrophic lateral sclerosis (ALS) has been hindered by both the complexity of the disease and decentralized research efforts. By fostering collaboration, standardization, and inclusivity, the Accelerating Medicines Partnership® (AMP®) ALS initiative aims to lay the foundation for future discoveries in ALS biomarkers and treatments.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in Neurosciences 医学-神经科学

CiteScore

26.50

自引率

1.30%

发文量

123

审稿时长

6-12 weeks

期刊介绍： For over four decades, Trends in Neurosciences (TINS) has been a prominent source of inspiring reviews and commentaries across all disciplines of neuroscience. TINS is a monthly, peer-reviewed journal, and its articles are curated by the Editor and authored by leading researchers in their respective fields. The journal communicates exciting advances in brain research, serves as a voice for the global neuroscience community, and highlights the contribution of neuroscientific research to medicine and society.